MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

Home・Akcijų sąrašas・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

4.39 -2.66

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.24

Max

4.51

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-12M -27M
Pardavimai	-5.3M 663K
P/E Sektoriaus vid.	22.5 57.05
Pelno marža	-3,998.492
Darbuotojai	69
EBITDA	-13M -27M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+202.43% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-180M 964M
Ankstesnė atidarymo kaina	7.05
Ankstesnė uždarymo kaina	4.39

Naujienos nuotaikos

By Acuity

50%

169 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

0.7658 / N/A Palaikymas ir pasipriešinimas

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-30 23:15; UTC

Svarbiausios naujienos

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

2026-03-30 22:36; UTC

Svarbiausios naujienos

Australian Government Rules Out Boots on the Ground in the Middle East

2026-03-30 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

2026-03-30 21:00; UTC

Uždarbis

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

2026-03-30 20:15; UTC

Svarbiausios naujienos

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

2026-03-30 23:40; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-30 23:40; UTC

Rinkos pokalbiai

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

2026-03-30 23:36; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

2026-03-30 23:12; UTC

Rinkos pokalbiai

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

2026-03-30 22:49; UTC

Rinkos pokalbiai

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

2026-03-30 22:44; UTC

Rinkos pokalbiai

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

2026-03-30 22:43; UTC

Rinkos pokalbiai

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

2026-03-30 22:42; UTC

Rinkos pokalbiai

South32 Should Go for Growth, Says New Bull -- Market Talk

2026-03-30 22:18; UTC

Rinkos pokalbiai

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

2026-03-30 22:05; UTC

Rinkos pokalbiai

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

2026-03-30 21:58; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Financial Agrees to Buy Bell Partners for $350M

2026-03-30 21:39; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

2026-03-30 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

2026-03-30 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

2026-03-30 21:25; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-30 21:25; UTC

Rinkos pokalbiai

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

2026-03-30 21:03; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

2026-03-30 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-03-30 20:09; UTC

Uždarbis

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

2026-03-30 20:00; UTC

Svarbiausios naujienos

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

202.43% į viršų

12 mėnesių prognozė

Vidutinis 13.67 USD 202.43%

Aukščiausias 17 USD

Žemiausias 11 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių CytomX Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.7658 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

169 / 349 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.